Tamoxifen: A Review of its Pharmacological Properties and Therapeutic Use in the Treatment of Breast Cancer
Synopsis: Tamoxifen1 is a triphenylethylene oestrogen antagonist which has partial oestrogen agonist activity in some species. Most therapeutic trials with tamoxifen have involved postmenopausal women with advanced breast cancer, about 25 to 60% of patients showing some improvement while receiving treatment (usually 20 or 40mg daily); however, poorly defined assessment criteria in some studies make it difficult to compare the results of different authors. 7 to 18% of patients have had complete clinical remissions lasting for a few months to several years.
Although few comparative studies with other treatments have been done, it nevertheless appears that tamoxifen is at least as effective as standard oestrogen or androgen therapy in postmenopausal women, while producing a lower incidence of troublesome adverse effects. In the only comparison with a cytotoxic treatment regimen, the response rates with tamoxifen and cytotoxic therapy were similar (41% versus 50%) in patients who were more than 5 years postmenopausal and had primarily soft-tissue involvement; but in patients who were within 2 to 5 years of their last menstrual period cytotoxic treatment was more effective. Similarly, most authors have reported a higher response rate with tamoxifen in women several years postmenopausal than in those more recently postmenopausal.
Tumours which contain oestrogen receptors respond more often to tamoxifen than those which do not.
Administering tamoxifen concomitantly with other chemotherapeutic agents such as cytotoxic drugs appears to increase the response rate, but as might be expected also increases the incidence of adverse reactions.
When used alone tamoxifen has been relatively well tolerated in all studies, the overall withdrawal rate due to side-effects being less than 3 %.
Pharmacodynamic Studies: In most animal species tamoxifen exerts antioestrogenic actions, although in some tests in rodents it produces weak or atypical oestrogenic reactions and it has appeared to produce some oestrogen-like effects in a few women receiving therapeutic doses. Tamoxifen inhibited or reversed the growth of some chemically-induced tumours in rats and decreased the frequency of tumour development when given concurrently with the carcinogenic agent dimethylbenzanthracene. In in vitro studies using human mammary tumour cell cultures, tamoxifen inhibited cellular reproduction when added to the culture medium of tumours containing oestrogen receptors, but had little or no effect in the absence of oestrogen receptors. The mechanism of its antioestrogenic as well as its antitumour activity probably involves competition with oestradiol for oestrogen receptor sites, preventing typical oestrogenic actions including oestrogen-stimulated nucleic acid synthesis.
Pharmacokinetic Studies: The absorption of orally-administered tamoxifen has not been well studied in humans, but maximum plasma levels of drug appear to occur several hours after oral ingestion. Distribution studies showing the extent of tumour uptake of tamoxifen have not been done. In animals the ovaries retained more radioactivity than other reproductive organs after a single labelled dose; and in the small number of patients who have been thus studied radioactivity in the uterus was higher than in serum 4 to 96 hours after a labelled dose. Metabolism studies in animals have shown hydroxylation to be the major metabolic route, the monohydroxylated metabolite being more active as an antioestrogen than tamoxifen, while the dihydroxylated metabolite was only weakly active.
In animals the bile was an important route of elimination of radioactivity after a labelled dose, with subsequent reabsorption of some of the biliary radioactivity. Excretion in humans appears to occur slowly, primarily via the faeces, the elimination half-life being more than 7 days in the few patients studied thus far.
Therapeutic Trials: Most trials with tamoxifen have been noncomparative studies in postmenopausal women with advanced, recurrent breast cancer. In many studies, varying criteria of response and a lack of sufficient information on factors such as time of evaluation and type and time of stopping previous treatment make comparisons of the individual study results difficult. However, in most studies about 25 to 60 % of patients have shown some response to treatment and 7 to 18% of patients have achieved complete remissions lasting for a few months to as long as several years. It thus appears that tamoxifen is at least as effective as standard hormonal therapy in postmenopausal women, although direct comparisons with these agents have not yet been reported. In a single comparison with a cytotoxic regimen, tamoxifen and cytotoxic treatment were comparably effective (41% and 50% response rates, respectively) in women more than 5 years postmenopausal who had primarily soft-tissue involvement; but cytotoxic therapy was more effective in women who were within 2 to 5 years of their last menstrual period. Indeed, many other authors have similarly reported that women several years postmenopausal respond more frequently to tamoxifen than those more recently postmenopausal. The number of premenopausal women treated to date is too small to clearly determine their response rate as compared with postmenopausal patients.
In most trials in which oestrogen receptor studies were done, there was a correlation between the presence of oestrogen receptors and a response to tamoxifen, although a few patients with oestrogen receptor-negative tumours have responded. As with other hormonal treatments of breast cancer, visceral metastases have responded less frequently than soft tissue, skin or, in some cases, bone involvement.
Combining tamoxifen with cytotoxic chemotherapy or with other hormonal agents, appears to increase the response rate as well as the incidence of serious adverse effects.
Side-Effects: Tamoxifen has been well tolerated in most postmenopausal patients studied, the overall incidence of withdrawal from treatment due to adverse effects being less than 3%. The most common side-effects are due to the drug’s antioestrogenic actions, and include hot flushes (10 to 20%) and less frequently pruritus vulvae and vaginal bleeding or discharge. Nausea and vomiting have been reported in about 10% of patients. Pain from bone metastases, especially during the early stage of therapy, has been reported by some patients but was often followed by a response to tamoxifen. Transient blood abnormalities (thrombocytopenia, mild leukopenia, decreased haemoglobin) have occurred but have not necessitated discontinuing treatment. Pulmonary emboli have been reported in a few cases during tamoxifen administration, but a causal relationship with drug treatment has not been clearly established.
Dosage: The recommended starting dosage of tamoxifen is 10mg twice daily. If a response does not occur within 1 month, the dose should be increased to 20mg twice daily.
KeywordsBreast Cancer Oestrogen Receptor Tamoxifen Advanced Breast Cancer Ifen
Unable to display preview. Download preview PDF.
- Barrett, A.: Discussion comments. Proceedings of a Symposium on Hormonal Control of Breast Cancer, Alderley Park, 24th September, p.40 (1975).Google Scholar
- Baum, M.: Comparison of ‘Nolvadex’ and cytotoxic agents. The Anti-oestrogen and Breast Cancer, Symposium, King’s College Cambridge, 28th–29th September (1977).Google Scholar
- Bratherton, Dr.: Discussion comments. The Hormonal Control of Breast Cancer, Proceedings of a Symposium in Manchester, p.39, 9th June (1976).Google Scholar
- Brewin, T.B.: Clinical experience with tamoxifen (ICI 46,474) in the management of breast cancer. Paper presented at the 8th International Congress of Chemotherapy, Athens, September (1973).Google Scholar
- Brule, G.: Co-operative clinical study of 178 patients treated with ‘Nolvadex’. The Hormonal Control of Breast Cancer, Proceedings of a Symposium in Manchester, p.35, 9th June (1976).Google Scholar
- Clarysse, A. and Mathe, G.: Malignant Diseases: in Avery (Ed), Drug Treatment, p.757 (ADIS Press, Sydney; Lea & Febiger, Philadelphia; Churchill Livingstone, Edinburgh 1976).Google Scholar
- Cole, M.P.; Jones, C.T.A. and Todd, I.D.H.: The treatment of advanced carcinoma of the breast with the antioestrogenic agent tamoxifen (ICI 46,474) — a series of 96 patients. Advances in Antimicrobial and Antineoplastic Chemotherapy 2: 529 (1971a).Google Scholar
- Emmens, C.W.: Inhibitors of implantation. Journal of Reproduction and Fertility Suppl. 18: 177 (1973).Google Scholar
- Fenwick, L.; Jones, R.L.; Naylor, B.; Poyser, N.L. and Wilson, N.H.: Production of prostaglandins by the pseudopregnant rat uterus, in vitro, and the effect of tamoxifen with the identification of 6-keto-prostaglandin F1α as a major product. British Journal of Pharmacology 59: 191 (1977).PubMedCrossRefGoogle Scholar
- Fiorentino, M.: Discussion comments. Proceedings of a Symposium on Hormonal Control of Breast Cancer, Alderley Park, 24th September, p.38 (1975).Google Scholar
- Greaves, M.; Atkins, D.; Ibbotson, K. and Martin, T.J.: Breast tumours, bone resorption and prostaglandins. Clinical Science and Molecular Medicine 54: 20 (1978).Google Scholar
- Horwitz, K.B. and McGuire, W.L.: Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. Journal of Clinical Investigation, in press (1978).Google Scholar
- Jordan, V.C.: The anti-tumour effect of tamoxifen in the dimethylbenzanthracene-induced rat mammary carcinoma model. Proceedings of a Symposium on Hormonal Control of Breast Cancer, Alderley Park, 24th September, p.11 (1975b).Google Scholar
- Jordan, V.C.: Use of the DMBA-induced rat mammary carcinoma system for the evaluation of tamoxifen treatment as a potential adjuvant therapy. The Anti-oestrogen and Breast Cancer, Symposium, King’s College, Cambridge, 28–29 Sept. (1977b).Google Scholar
- Joslin, C.A.F.: The place of simple endocrine therapy in breast cancer. The Hormonal Control of Breast Cancer, Proceedings of a Symposium in Manchester, p.43, 9th June (1976).Google Scholar
- Jungi, F. and Wagenknecht, L.: Tamoxifen alone or combined with multiple drug chemotherapy in disseminated breast carcinoma. Proceedings of the American Association for Cancer Research and Amer. Soc. Clin. Oncol. 17(Abstract C-181): 312 (1977).Google Scholar
- Kurano, A.; Katagiri, H.; Nakamura, M.; Nakamura, G.; Shibata, C.; Nagata, Y. and Kusuda, M.: Changes in blood hormone levels during treatment with tamoxifen, a new drug to induce ovulation. Japanese Society of Fertility and Sterility, October 28th and 29th (1976).Google Scholar
- Lerner, H.J.; Band, P.R.; Israel, L. and Leung, B.S.: Phase II study of tamoxifen: Report of 74 patients with stage IV breast cancer. Cancer Treatment Reports 60: 1431 (1976). Also published by Band, P.R.: Stage II study of tamoxifen in breast cancer patients. Proceedings of a Symposium on Hormonal Control of Breast Cancer, Alderley Park, 24th September, p.35 (1975).PubMedGoogle Scholar
- Lerner, H.; Godwin, M.C.; Vach, B.K. and Trench, L.: Low dose tamoxifen in the treatment of metastatic breast cancer at the Pennsylvania Hospital. International Journal of Radiation Oncology, Biology, Physics 2(Suppl. 1): 78 (1977).Google Scholar
- Lippman, M.: Oestrogen-dependent human breast cancer in continuous tissue culture. Proceedings of a Symposium on Hormonal Control of Breast Cancer, Alderley Park, 24th September, p.25 (1975a).Google Scholar
- Lippman, M.: Discussion comments. Proceedings of a Symposium on Hormonal Control of Breast Cancer, Alderley Park, 24th September, p.41 (1975b).Google Scholar
- Magarey, C.: Tamoxifen in the treatment of breast cancer. Current Therapeutics 19(No. 1): 17 (1978).Google Scholar
- Masala, A.; Delitala, G.; Lo Dico, G.; Stoppeiii, I.; Alagna, S. and Devilla, L.: Inhibition of lactation and inhibition of prolactin release after mechanical breast stimulation in puerperal women given tamoxifen or placebo. British Journal of Obstetrics and Gynaecology 85: 134 (1978).PubMedCrossRefGoogle Scholar
- Morgan, L.R.; Posey, L.E.; Krementz, E.T.; Hawley, W. and Beasley, R.W.: Tamoxifen plus CMF for advanced breast cancer. Proceedings of the American Association for Cancer Research and the Amer. Soc. Clin. Oncol. 18(Abstract C-166): 308 (1977).Google Scholar
- Nordenskjold, B.; Lowhagen, T. and Zajicek, J.: [3H] thymidine incorporation into DNA of mammary carcinoma before and after endocrine therapy. Proceedings of a Symposium on Hormonal Control of Breast Cancer, Alderley Park, 24th September, p.43 (1975).Google Scholar
- Pearson, O.H.: Anti-oestrogen treatment in stage IV breast cancer. The Anti-oestrogen and Breast Cancer, Symposium, King’s College Cambridge, 28th–29th September (1977).Google Scholar
- Ritchie, G.: The direct inhibition of prostaglandin synthetase of human breast cancer tumour tissue by ‘Nolvadex’. The Anti-oestrogen and Breast Cancer, Symposium, King’s College Cambridge, 28th–29th September (1977).Google Scholar
- Roberts, M.: Discussion comments. Proceedings of a Symposium on Hormonal Control of Breast Cancer, Alderley Park, 24th September, p.40 (1975).Google Scholar
- Roberts, M.M.: Tamoxifen versus oestrogen and androgen in postmenopausal women with breast cancer. The Hormonal Control of Breast Cancer, Proceedings of a Symposium in Manchester, p.40, 9th June (1976).Google Scholar
- Senior, B.E.; Cawood, M.L.; Oakey, R.E.; McKiddie, J.M. and Siddle, D.R.: A comparison of the effects of clomiphene and tamoxifen treatment on the concentrations of oestradiol and progesterone in the peripheral plasma of infertile women. Journal of Endocrinology, in press (1978).Google Scholar
- Sponzo, R.W.; Barkley, J.M.; Horton, J. and Cunningham, T.J.: Tamoxyphen (NSC 180,973) in the management of advanced breast cancer. Proceedings of the American Association for Cancer Research and the Amer. Soc. Clin. Oncol. 18(Abstract 270): 68 (1976).Google Scholar
- Siddal, R.A. and Baker, S.S.B. de C.: The mechanisms of production of experimental foetal abnormalities by some hormonally active compounds. Teratology 4: 501 (1971).Google Scholar
- Tajima, C.; Tamaki, Y. and Takamizawa, H.: Trials of tamoxifen for the induction of ovulation. Acta Obstetrica et Gynaecologica Japan 29: 57 (1977).Google Scholar
- Walpole, A.L.: The anti-oestrogenic activity of ‘Nolvadex’ in laboratory animals. Proceedings of a Symposium on Hormonal Control of Breast Cancer, Alderley Park, 24th September, p.5 (1975).Google Scholar
- Ward, H.W.C.: Antioestrogens in treatment of breast cancer. British Medical Journal 2: 500 (1974).Google Scholar
- Ward, H.W.C.: Clinical experience with anti-hormone therapy. Proceedings of a Symposium on Hormonal Control of Breast Cancer, Alderley Park, 24th September, p.53 (1975). Also published in part in British Medical Journal 1: 13 (1973).Google Scholar
- Ward, H.W.C.; Arthur, K.; Banks, A.J.; Brown, I.; Bond, W.H.; Freeman, W.E.; Holme, G.M.; Jones, W.G.; Ostrowski, M.J. and Newsholme, G.A.: Anti-oestrogen therapy for breast cancer. A report on 300 patients treated with tamoxifen. Clinical Oncology, in press (1978). Also published in part by Ward, 1973; 1975.Google Scholar
- Watson, J.; Alam, M.; Anderson, F.B. and Heald, P.J.: The effect of ICI 46,474 (tamoxifen) on hormone concentrations during early pregnancy in the rat. Biochemical Society Transactions 2: 982 (1974).Google Scholar
- Willis, J.K.: Investigations of hormone changes in breast cancer patients before and after treatment with Nolvadex. Proceedings of a Symposium on Hormonal Control of Breast Cancer, Alderley Park, 24th September, p.59 (1975).Google Scholar